Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alpha Tau Medical Ltd ( (DRTS) ) has provided an announcement.
On December 18, 2025, Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026, and will hold one-on-one meetings with institutional investors during the event. The presentation is expected to highlight the company’s recent achievements and outline upcoming data milestones for its Alpha DaRT solid-tumor therapy, signaling an effort to raise Alpha Tau’s visibility with global healthcare investors and potentially strengthen its position within the oncology therapeutics space as it advances toward further clinical and commercial development.
The most recent analyst rating on (DRTS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., founded in 2016 and based in Israel, is an oncology therapeutics company focused on the research, development and potential commercialization of Alpha DaRT, an innovative alpha-radiation cancer therapy designed for the treatment of solid tumors. The Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology uses intratumoral delivery of radium-224 impregnated sources to release short-lived alpha-emitting atoms that aim to selectively destroy tumor tissue while sparing surrounding healthy tissue.
Average Trading Volume: 122,665
Technical Sentiment Signal: Buy
Current Market Cap: $438.3M
For detailed information about DRTS stock, go to TipRanks’ Stock Analysis page.